Wells Fargo & Company MN Purchases 20,430 Shares of Veru Inc. (NASDAQ:VERU)

Wells Fargo & Company MN lifted its position in Veru Inc. (NASDAQ:VERU) by 37.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 75,512 shares of the company’s stock after buying an additional 20,430 shares during the quarter. Wells Fargo & Company MN’s holdings in Veru were worth $49,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Gladstone Institutional Advisory LLC boosted its position in Veru by 52.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock worth $57,000 after purchasing an additional 30,000 shares during the period. Jane Street Group LLC boosted its position in Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after purchasing an additional 56,736 shares during the period. SG Americas Securities LLC boosted its position in Veru by 132.4% during the fourth quarter. SG Americas Securities LLC now owns 153,656 shares of the company’s stock worth $100,000 after purchasing an additional 87,528 shares during the period. Atria Investments Inc boosted its position in Veru by 21.2% during the fourth quarter. Atria Investments Inc now owns 171,707 shares of the company’s stock worth $112,000 after purchasing an additional 30,043 shares during the period. Finally, Barclays PLC boosted its position in Veru by 309.2% during the third quarter. Barclays PLC now owns 184,777 shares of the company’s stock worth $142,000 after purchasing an additional 139,617 shares during the period. Institutional investors own 47.16% of the company’s stock.

Veru Stock Down 1.0%

Shares of Veru stock opened at $0.52 on Wednesday. The stock has a market capitalization of $75.48 million, a P/E ratio of -1.98 and a beta of -0.74. The stock has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $0.63. Veru Inc. has a 12-month low of $0.45 and a 12-month high of $1.57.

Veru (NASDAQ:VERU) last announced its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. Sell-side analysts anticipate that Veru Inc. will post -0.22 earnings per share for the current year.

Insider Transactions at Veru

In other Veru news, Director Michael L. Rankowitz purchased 95,279 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was bought at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the acquisition, the director now directly owns 195,279 shares in the company, valued at $107,403.45. This represents a 95.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.90% of the company’s stock.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.